2026-06-27

OSINT: Bahrain Condemns Iranian Attacks on Its Territory

Oil -3.74%: significant decline on the session

CFTC COPPER speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

OSINT: Ukrainian Flamingo missiles strike Russia's Titan‑Barrikady defense plant

Oil -3.74%: significant decline on the session

CFTC COPPER speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

Gold +1.20%: significant gain on the session

ETH open interest -68.6% — OI collapse

SOL open interest +250.5% — OI surge

BTC open interest -44.8% — OI collapse

SOL open interest +255.5% — OI surge

BTC open interest +230.4% — OI surge

ETH open interest +219.2% — OI surge

SOL DEX volume/liquidity ratio elevated (0.63x): on-chain trade volume 0.63x liquidity

Phase 3 trial terminated early — JOHNSON A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Tr

Phase 3 trial terminated early — ELI A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migrain

Phase 3 trial terminated early — BRISTOL Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and D

Phase 3 trial terminated early — AMGEN Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Ob

Phase 3 trial terminated early — AbbVie Study of BOTOX Injections in Prevention of Migraine in Adult Participants With E

Phase 3 trial terminated early — Merck A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemothera

Phase 3 trial terminated early — Merck Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host

Phase 3 trial terminated early — Merck TRUST Study: Raptiva ® in Hand & Foot Psoriasis

Phase 3 trial terminated early — PFIZER The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital

Phase 3 trial terminated early — PFIZER A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

Phase 3 trial terminated early — PFIZER Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therap

Phase 3 trial terminated early — PFIZER A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participa

Phase 3 trial terminated early — PFIZER A Ten-Week Study Evaluating The Effectiveness And Safety Of Zoloft In Children A

Phase 3 trial terminated early — PFIZER A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzh

Phase 3 trial terminated early — ABBOTT A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectivenes

Phase 3 trial terminated early — ABBOTT Pilot Assessment of Lopinavir/Ritonavir and Maraviroc

Phase 3 trial terminated early — ABBOTT Growth and Tolerance of Healthy Term Infants to a New Infant Formula

Phase 3 trial terminated early — GILEAD Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in A

Phase 3 trial terminated early — GILEAD Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH

Activist 13D filing — strategic alternative

Activist 13D filing — strategic alternative

Sanofi search volume spiked +37 pts — unusual interest

Owens Corning search volume spiked +60 pts — unusual interest

LOWES COMPANIES INC search volume spiked +51 pts — unusual interest

Firefly Aerospace Inc. search volume spiked +83 pts — unusual interest

CVS HEALTH Corp search volume spiked +88 pts — unusual interest

Q1-2026: Beat consensus by 357.5% — EPS $0.35 vs $0.0765 estimate

Q3-2025: Missed consensus by 242.6% — EPS $-0.4 vs $0.2805 estimate

Q4-2025: Missed consensus by 79.4% — EPS $0.3 vs $1.4581 estimate

Q4-2025: Beat consensus by 131.0% — EPS $0.07 vs $0.0303 estimate

Q1-2026: Beat consensus by 15.5% — EPS $0.21 vs $0.1818 estimate

Q2-2025: Beat consensus by 81.8% — EPS $0.56 vs $0.3081 estimate

Q4-2019: Beat consensus by 37.0% — EPS $-192000 vs $-304616 estimate

Q2-2025: Missed consensus by 26.0% — EPS $-0.176 vs $-0.1397 estimate

Q1-2026: Beat consensus by 15.1% — EPS $-0.2 vs $-0.2357 estimate

Q3-2025: Missed consensus by 94.8% — EPS $-0.31 vs $-0.1591 estimate

Q3-2025: Beat consensus by 26.1% — EPS $-0.69 vs $-0.9343 estimate

Q1-2026: Beat consensus by 21.6% — EPS $-0.16 vs $-0.204 estimate

Q4-2025: Beat consensus by 37.9% — EPS $-0.22 vs $-0.3545 estimate

Q2-2025: Beat consensus by 21.6% — EPS $-3.47 vs $-4.4248 estimate

Q1-2026: Beat consensus by 217.6% — EPS $0.01 vs $-0.0085 estimate

Q3-2025: Missed consensus by 100.0% — EPS $0 vs $0.0041 estimate

Q2-2025: Beat consensus by 64.4% — EPS $-0.01 vs $-0.0281 estimate

Q4-2025: Beat consensus by 33.6% — EPS $0.06 vs $0.0449 estimate

Q2-2025: Missed consensus by 5.8% — EPS $-1.07 vs $-1.0111 estimate

Q4-2025: Missed consensus by 7.8% — EPS $-1.31 vs $-1.2153 estimate

Q1-2026: Beat consensus by 14.2% — EPS $-0.42 vs $-0.4896 estimate

Q2-2025: Beat consensus by 27.5% — EPS $-0.37 vs $-0.51 estimate

Q3-2025: Beat consensus by 53.1% — EPS $-0.34 vs $-0.7242 estimate

Q4-2025: Beat consensus by 36.0% — EPS $-0.32 vs $-0.4998 estimate

Q2-2025: Beat consensus by 14.7% — EPS $0.75 vs $0.654 estimate

Q3-2025: Missed consensus by 7.0% — EPS $1.24 vs $1.3329 estimate

Q1-2026: Missed consensus by 623.1% — EPS $-0.41 vs $-0.0567 estimate

Q4-2021: Missed consensus by 5.0% — EPS $-22.5 vs $-21.42 estimate

Q3-2021: Missed consensus by 178.6% — EPS $-40.5 vs $-14.535 estimate

Q2-2022: Missed consensus by 35.6% — EPS $-8.3 vs $-6.12 estimate

Q1-2026: Missed consensus by 1154.1% — EPS $-2.28 vs $-0.1818 estimate

Q1-2020: Missed consensus by 100.0% — EPS $0 vs $0.0612 estimate

Q4-2019: Beat consensus by 9635.9% — EPS $14.59 vs $-0.153 estimate

Q4-2024: Missed consensus by 233.3% — EPS $-0.68 vs $-0.204 estimate

Q1-2025: Beat consensus by 19.7% — EPS $-0.59 vs $-0.7344 estimate

Q2-2025: Beat consensus by 31.1% — EPS $-0.45 vs $-0.6528 estimate

Q3-2024: Missed consensus by 96.1% — EPS $-0.28 vs $-0.1428 estimate

Q4-2025: Beat consensus by 27.7% — EPS $-1.8 vs $-2.4888 estimate

Q1-2026: Missed consensus by 7.1% — EPS $-1.53 vs $-1.428 estimate

Q2-2026: Missed consensus by 43.3% — EPS $-1.25 vs $-0.8721 estimate

Q2-2025: Missed consensus by 98.0% — EPS $-0.06 vs $-0.0303 estimate

Q1-2026: Beat consensus by 108.3% — EPS $0.01 vs $-0.1212 estimate

Q4-2025: Missed consensus by 566.7% — EPS $-0.09 vs $-0.0135 estimate

Q3-2025: Missed consensus by 11.3% — EPS $-0.06 vs $-0.0539 estimate

Q4-2025: Missed consensus by 22.2% — EPS $1.17 vs $1.5039 estimate

Q2-2025: Missed consensus by 11.4% — EPS $1.09 vs $1.2298 estimate

Q3-2025: Missed consensus by 27.9% — EPS $0.86 vs $1.1923 estimate

Q4-2025: Missed consensus by 298.1% — EPS $-0.67 vs $-0.1683 estimate

Q2-2025: Beat consensus by 44.0% — EPS $-0.06 vs $-0.1071 estimate

Q3-2025: Missed consensus by 66.9% — EPS $-0.12 vs $-0.0719 estimate

Q3-2025: Beat consensus by 186.6% — EPS $0.06 vs $-0.0693 estimate

Q2-2025: Beat consensus by 8.2% — EPS $0.12 vs $0.1109 estimate

Q4-2025: Beat consensus by 32.8% — EPS $-0.09 vs $-0.1339 estimate

Q1-2026: Beat consensus by 124.0% — EPS $0.11 vs $0.0491 estimate

Q2-2025: Beat consensus by 47.7% — EPS $0.35 vs $0.237 estimate

Q3-2025: Beat consensus by 5.1% — EPS $0.35 vs $0.3329 estimate

Q1-2026: Beat consensus by 10.1% — EPS $0.25 vs $0.2271 estimate

Q2-2017: Beat consensus by 16.2% — EPS $-5.5 vs $-6.565 estimate

Q1-2017: Beat consensus by 8.6% — EPS $-6 vs $-6.565 estimate

Q3-2025: Beat consensus by 6.4% — EPS $1.76 vs $1.6538 estimate

Q2-2026: Beat consensus by 7.8% — EPS $2.27 vs $2.1054 estimate

Q1-2026: Beat consensus by 30.0% — EPS $2.17 vs $1.6687 estimate

Q4-2025: Beat consensus by 10.9% — EPS $2.09 vs $1.8847 estimate

Q3-2025: Missed consensus by 853.4% — EPS $-0.44 vs $0.0584 estimate

Q1-2026: Missed consensus by 106.3% — EPS $-5.2 vs $-2.5201 estimate

Q4-2025: Beat consensus by 64.6% — EPS $-0.44 vs $-1.2412 estimate

Q1-2025: Missed consensus by 52.1% — EPS $-0.47 vs $-0.309 estimate

Q3-2025: Missed consensus by 6.2% — EPS $-0.32 vs $-0.3013 estimate

Q2-2025: Missed consensus by 5.6% — EPS $-0.31 vs $-0.2935 estimate

Q4-2025: Missed consensus by 10.0% — EPS $-0.3 vs $-0.2728 estimate

Q1-2026: Beat consensus by 60.7% — EPS $-0.13 vs $-0.3311 estimate

Q4-2025: Missed consensus by 108.3% — EPS $-0.29 vs $-0.1392 estimate

Q2-2025: Beat consensus by 23.8% — EPS $-0.05 vs $-0.0656 estimate

Q3-2025: Missed consensus by 39.1% — EPS $-0.08 vs $-0.0575 estimate

Q1-2026: Missed consensus by 404.1% — EPS $-0.92 vs $-0.1825 estimate

Q3-2025: Beat consensus by 6.0% — EPS $0.47 vs $0.4434 estimate

Q1-2026: Missed consensus by 38.3% — EPS $0.25 vs $0.4049 estimate

Q2-2025: Missed consensus by 7.8% — EPS $0.42 vs $0.4553 estimate

Q2-2025: Beat consensus by 9.0% — EPS $2.86 vs $2.6232 estimate

Q3-2025: Beat consensus by 281.2% — EPS $0.17 vs $0.0446 estimate

Q1-2026: Beat consensus by 106.2% — EPS $0.08 vs $0.0388 estimate

Q2-2025: Missed consensus by 16.3% — EPS $0.1 vs $0.1195 estimate

Q4-2025: Beat consensus by 100.0% — EPS $0 vs $-0.0102 estimate

Q2-2025: Beat consensus by 15.5% — EPS $3.09 vs $2.6752 estimate

Q1-2026: Beat consensus by 11.9% — EPS $3.04 vs $2.7166 estimate

Q4-2025: Beat consensus by 10.8% — EPS $2.62 vs $2.3636 estimate

Q3-2025: Beat consensus by 9.4% — EPS $2.5 vs $2.2855 estimate

Q3-2025: Beat consensus by 13.7% — EPS $0.33 vs $0.2902 estimate

Q1-2026: Missed consensus by 11.2% — EPS $0.79 vs $0.8901 estimate

Q2-2025: Beat consensus by 21.9% — EPS $0.38 vs $0.3118 estimate

Q4-2025: Beat consensus by 10.8% — EPS $0.47 vs $0.4241 estimate

Q3-2024: Missed consensus by 30.3% — EPS $69.68 vs $99.99 estimate

Q2-2025: Missed consensus by 17.1% — EPS $47.75 vs $57.57 estimate

Q4-2024: Missed consensus by 52.4% — EPS $-50.78 vs $-33.33 estimate

Q1-2025: Beat consensus by 193.3% — EPS $13.19 vs $-14.14 estimate

Q2-2025: Beat consensus by 5.7% — EPS $2.7 vs $2.5553 estimate

Q3-2025: Missed consensus by 375.2% — EPS $-0.48 vs $-0.101 estimate

Q2-2025: Beat consensus by 37.0% — EPS $-0.14 vs $-0.2222 estimate

Q1-2026: Missed consensus by 218.5% — EPS $-0.15 vs $-0.0471 estimate

Q4-2025: Missed consensus by 122.8% — EPS $-0.18 vs $-0.0808 estimate

Q4-2025: Beat consensus by 5.9% — EPS $3.15 vs $2.9742 estimate

Q2-2025: Beat consensus by 5.2% — EPS $2.78 vs $2.6428 estimate

Q1-2026: Beat consensus by 6.1% — EPS $3.22 vs $3.034 estimate

Q2-2023: Beat consensus by 21.6% — EPS $-6 vs $-7.65 estimate

Q4-2022: Missed consensus by 7.8% — EPS $-16.5 vs $-15.3 estimate

Q3-2023: Beat consensus by 26.5% — EPS $-4.5 vs $-6.12 estimate

Q1-2023: Missed consensus by 17.6% — EPS $-9 vs $-7.65 estimate

Q4-2025: Missed consensus by 25.8% — EPS $0.43 vs $0.5794 estimate

Q3-2025: Beat consensus by 16.0% — EPS $0.55 vs $0.4743 estimate

Q3-2025: Beat consensus by 6.3% — EPS $0.23 vs $0.2163 estimate

Q4-2025: Beat consensus by 19.8% — EPS $0.29 vs $0.2421 estimate

Q2-2025: Beat consensus by 40.6% — EPS $-0.03 vs $-0.0505 estimate

Q3-2025: Beat consensus by 50.5% — EPS $-0.02 vs $-0.0404 estimate

Q4-2025: Beat consensus by 34.0% — EPS $-0.02 vs $-0.0303 estimate

Q1-2025: Beat consensus by 31.7% — EPS $-2.76 vs $-4.0392 estimate

Q2-2025: Beat consensus by 47.2% — EPS $-1.68 vs $-3.1824 estimate

Q4-2024: Beat consensus by 32.3% — EPS $-3.48 vs $-5.1408 estimate

Q3-2025: Beat consensus by 10.8% — EPS $-2.292 vs $-2.5704 estimate

Q3-2025: Beat consensus by 14.6% — EPS $0.59 vs $0.515 estimate

Q2-2025: Missed consensus by 5.9% — EPS $0.42 vs $0.4463 estimate

Q1-2026: Missed consensus by 23.0% — EPS $0.39 vs $0.5068 estimate

Q1-2026: Missed consensus by 132.4% — EPS $-0.03 vs $0.0927 estimate

Q3-2025: Beat consensus by 17.6% — EPS $0.36 vs $0.3062 estimate

Q2-2025: Beat consensus by 27.9% — EPS $0.36 vs $0.2815 estimate

Q4-2025: Missed consensus by 12.2% — EPS $0.35 vs $0.3987 estimate

Q4-2024: Missed consensus by 9.8% — EPS $0.79 vs $0.8754 estimate

Q2-2025: Missed consensus by 31.9% — EPS $0.55 vs $0.808 estimate

Q1-2026: Beat consensus by 70.9% — EPS $0.34 vs $0.1989 estimate

Q4-2025: Missed consensus by 62.5% — EPS $0.17 vs $0.4539 estimate

Q3-2025: Beat consensus by 65.8% — EPS $0.62 vs $0.374 estimate

Q2-2025: Beat consensus by 90.6% — EPS $0.44 vs $0.2308 estimate

Q3-2024: Missed consensus by 63.8% — EPS $-1.22 vs $-0.7446 estimate

Q2-2024: Missed consensus by 82.4% — EPS $-0.93 vs $-0.51 estimate

Q1-2024: Beat consensus by 36.3% — EPS $-0.39 vs $-0.612 estimate

Q2-2025: Beat consensus by 9.2% — EPS $1.53 vs $1.4006 estimate

Q1-2026: Beat consensus by 33.4% — EPS $2.24 vs $1.6788 estimate

Q3-2025: Beat consensus by 10.5% — EPS $1.05 vs $0.9504 estimate

Q4-2025: Beat consensus by 40.2% — EPS $1.85 vs $1.3199 estimate

Q2-2026: Missed consensus by 24.2% — EPS $0.65 vs $0.8578 estimate

Q3-2026: Missed consensus by 116.9% — EPS $-0.08 vs $0.4743 estimate

Q1-2027: Missed consensus by 1864.7% — EPS $-0.18 vs $0.0102 estimate

Q1-2026: Beat consensus by 137.7% — EPS $0.05 vs $-0.1326 estimate

Q4-2025: Beat consensus by 37.6% — EPS $-0.31 vs $-0.4965 estimate

Q2-2025: Missed consensus by 9.5% — EPS $-0.8 vs $-0.7307 estimate

Q1-2026: Missed consensus by 781.7% — EPS $-0.85 vs $-0.0964 estimate

Q3-2025: Missed consensus by 35.7% — EPS $-1.17 vs $-0.8622 estimate

Q1-2022: Missed consensus by 131.6% — EPS $-0.6 vs $1.8972 estimate

Q4-2021: Beat consensus by 360.8% — EPS $0.47 vs $0.102 estimate

Q3-2021: Missed consensus by 130.2% — EPS $-0.32 vs $1.0608 estimate

Q1-2026: Missed consensus by 14.8% — EPS $0.95 vs $1.1152 estimate

Q3-2025: Beat consensus by 10.4% — EPS $1.16 vs $1.0506 estimate

Q2-2025: Beat consensus by 5.7% — EPS $1.2 vs $1.1356 estimate

Q4-2025: Beat consensus by 23.7% — EPS $0.67 vs $0.5417 estimate

Q1-2026: Beat consensus by 5.1% — EPS $-0.11 vs $-0.1159 estimate

VIX at 18.4: CAUTION territory

OSINT: First Ultra All-Inclusive Resort Opens in Russia, Managed by Global Hotel Chain